Search results
1 company and 8 research reports found for "Proximagen Group"
Company results
- Proximagen Group
Proximagen is a UK biotech company specialising in the development of treatments for CNS diseases. I...
Sector reports
No sector reports have been found.
Research results
Proximagen Group
A new strategic partner
Update | Pharmaceutical & Healthcare | 04/10/2011Proximagen has entered into a strategic co-development partnership with CNS specialist Lundbeck, which includes a £10.3m equity investment at 180...
Proximagen Group
Taking the next steps
Review | Pharmaceutical & Healthcare | 01/08/2011Proximagen’s strategic goal is sustainable revenue generation, with a longer-term plan to become a European speciality FIPCO in neurology. It ha...
Proximagen Group
Steps to sustainability
Outlook | Pharmaceutical & Healthcare | 26/04/2011Proximagen is a UK-based CNS specialist that has built a pipeline of 15 CNS and other programmes primarily through consolidation. The company has long...
Proximagen Group
GSK assets acquired
Update | Pharmaceutical & Healthcare | 22/12/2010Proximagen has announced an exclusive deal with GlaxoSmithKline to acquire global rights to two drug development programmes for CNS indications. Both ...
Proximagen Group
A done deal
Update | Pharmaceutical & Healthcare | 06/08/2010The divestment of sabcomeline to BrainCells Inc means Proximagen has now partnered both of the clinical assets obtained through its acquisition of Min...
Proximagen Group
Strategic execution
Update | Pharmaceutical & Healthcare | 23/04/2010Proximagen’s first clinical stage out-licensing deal, the licensing of North American tonabersat rights to Upsher Smith (a private US pharmaceutical...
Proximagen Group
Acquiring scale in CNS
Outlook | Pharmaceutical & Healthcare | 01/04/2010Proximagen has, through acquisition, expanded and diversified its pipeline from five preclinical products in neurodegenerative disease, to 14 CNS prog...
Proximagen Group
Pipeline expansion plans
Update | Pharmaceutical & Healthcare | 26/03/2009Proximagen offers an essentially pure-play investment in Parkinson’s disease, with five R&D programmes in this therapy area, all currently at the...
